Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy

Danielle N Drury-Stewart, Kerry W Lannert, Dominic W Chung, Gayle T Teramura, James C Zimring, Barbara A Konkle, Hilary S Gammill, Jill M Johnsen, Danielle N Drury-Stewart, Kerry W Lannert, Dominic W Chung, Gayle T Teramura, James C Zimring, Barbara A Konkle, Hilary S Gammill, Jill M Johnsen

Abstract

Background: The coagulation protein von Willebrand Factor (VWF) is known to be elevated in pregnancy. However, the timing and nature of changes in VWF and associated parameters throughout pregnancy are not well understood.

Objectives: To better understand the changes in VWF provoked by pregnancy, we studied VWF-associated parameters in samples collected over the course of healthy pregnancies.

Methods: We measured VWF antigen (VWF:Ag), VWF propeptide (VWFpp), Factor VIII (FVIII), and ADAMTS13 activity in samples collected from 46 women during pregnancy and at non-pregnant baseline. We also characterized pregnant vs. non-pregnant VWF multimer structure in 21 pregnancies, and performed isoelectric focusing (IEF) of VWF in two pregnancies which had samples from multiple trimesters.

Results: VWF:Ag and FVIII levels were significantly increased during pregnancy. ADAMTS13 activity was unchanged. VWFpp levels increased much later in pregnancy than VWF:Ag, resulting in a progressive decrease in VWFpp:Ag ratios. FVIII:VWF ratios also decreased in pregnancy. Most pregnancies exhibited a clear loss of larger VWF multimers and altered VWF triplet structure. Further evidence of acquired VWF qualitative changes in pregnancy was found in progressive, reversible shifts in VWF IEF patterns over gestation.

Conclusions: These data support a new view of pregnancy in which VWF can acquire qualitative changes associated with advancing gestational age. Modeling supports a scenario in which both increased VWF production and doubling of the VWF half-life would account for the data observed. We propose that gestation induces a prolongation in VWF survival, which likely contributes to increased total VWF levels and altered VWF structure.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. VWF-associated parameter data in 46…
Figure 1. VWF-associated parameter data in 46 pregnancies.
Values for VWF:Ag (A), FVIII (B), VWFpp (C), FVIII:VWF Ratio (D), VWFpp:Ag Ratio (E) are presented at each time point (non-pregnant baseline n = 46, 1st trimester n = 24, 2nd trimester n = 38, 3rd trimester n = 46). The median, 25th and 75th percentiles (boxed), 1 SD (bars), and individual outlying data points (black dots) are shown for each parameter at each time point. Statistically significant differences from baseline (p<0.05 by one-way ANOVA followed by all pairwise multiple comparisons) are indicated by asterisks (*). Values can be found in Table 2.
Figure 2. Changes in VWF-associated parameters from…
Figure 2. Changes in VWF-associated parameters from baseline in 46 pregnancies.
The changes in VWF parameters normalized to baseline are displayed longitudinally over pregnancy for time points sampled in pre-pregnancy n = 14, 1st trimester n = 24, 2nd trimester n = 38, 3rd trimester n = 44, 38wks n = 12, and postpartum n = 41. Asterisks (*) indicate p<0.05 compared to postpartum values (one-way ANOVA, all pairwise multiple comparisons). Standard deviations, means, 25th, and 75th percentiles are omitted for clarity and can be found in Table 4.
Figure 3. Loss of higher weight VWF…
Figure 3. Loss of higher weight VWF multimers in pregnancy.
A normalized 1% multimer gel (A) and densitometry (B) of plasma VWF multimers from a single pregnancy demonstrating the most commonly observed pattern of shifted VWF multimers (arrows) in the second trimester (orange) and third trimester (red) compared to baseline VWF (blue).
Figure 4. Change in VWF triplet structure…
Figure 4. Change in VWF triplet structure in pregnancy.
A normalized high resolution 2.6% multimer gel (A) and densitometry (B) of the same pregnancy shown in Fig 3 demonstrating the most commonly observed pattern of shifted VWF triplet structure with relative loss of height of the major band in the 3rd trimester (red) compared to baseline (blue).
Figure 5. Shift in isoelectric focus (IEF)…
Figure 5. Shift in isoelectric focus (IEF) pattern in pregnancy.
A. A normalized plasma isoelectric focusing gel from the same pregnancy as shown in Figs 3 and 4 immunoblotted for VWF. B. Densitometry tracings demonstrate the progressive shift in VWF isolectric focus in the 2nd (orange) and 3rd (red) trimesters. In the 3rd trimester, the band volume ratio of VWF in the doublet has shifted (3∶1 to nearly 2∶1) and the upper VWF band has shifted towards the lower pH focused VWF band.

References

    1. Favaloro EJ, Mehrabani PA, Koutts J (1997) Laboratory Assessment of von Willebrand Factor: Altered Interpretation of Laboratory Data, and Altered Diagnosis of von Willebrand's Disease. Clinical and Applied Thrombosis/Hemostasis 3: 110–118.
    1. Lenting PJ, Denis CV, Wohner N (2013) Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target. Curr Vasc Pharmacol 11: 448–456. CVP-54233 [pii].
    1. Johnsen JM, Ginsburg D (2010) von Willebrand Disease. In: Kaushansky K, Licthman MA, Beutler E, Kipps TJ, Seligsohn U, et al., editors. Williams Hematology. New York: McGraw Hill, Inc. pp. 2069–2087.
    1. Casonato A, Daidone V, Padrini R (2011) Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. Semin Thromb Hemost 37: 456–463 10.1055/s-0031-1281029 [doi]
    1. Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, et al. (2013) VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 121: 2336–2339 blood-2012-09-455089 [pii];10.1182/blood-2012-09-455089 [doi]
    1. Stockschlaeder M, Schneppenheim R, Budde U (2014) Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 25: 206–216 10.1097/MBC.0000000000000065 [doi]
    1. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488–494.
    1. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151: 933–938.
    1. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, et al. (1999) Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 94: 730–734.
    1. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, et al. (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143: 697–706.
    1. Marik PE, Plante LA (2008) Venous thromboembolic disease and pregnancy. N Engl J Med 359: 2025–2033.
    1. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD (2001) Venous thromboembolism in pregnancy and the puerperium: incidence and additional risk factors from a London perinatal database. BJOG 108: 56–60.
    1. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ (1983) Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet 21: 327–331.
    1. Brenner B (2004) Haemostatic changes in pregnancy. Thromb Res 114: 409–414.
    1. Sie P, Caron C, Azam J, Goudemand J, Grandjean H, et al. (2003) Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 121: 897–903.
    1. Castaman G (2013) Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease. Mediterr J Hematol Infect Dis 5: e2013052 10.4084/MJHID.2013.052 [doi];mjhid-5-1-e2013052 [pii]
    1. Saha P, Stott D, Atalla R (2009) Haemostatic changes in the puerperium ‘6 weeks postpartum’ (HIP Study) - implication for maternal thromboembolism. BJOG 116: 1602–1612.
    1. Butenas S, Parhami-Seren B, Mann KG (2009) The influence of von Willebrand factor on factor VIII activity measurements. J Thromb Haemost 7: 132–137 JTH3210 [pii];10.1111/j.1538-7836.2008.03210.x [doi]
    1. Wu JJ, Fujikawa K, Lian EC, McMullen BA, Kulman JD, et al. (2006) A rapid enzyme-linked assay for ADAMTS-13. Journal of Thrombosis and Haemostasis 4: 129–136 10.1111/j.1538-7836.2005.01677.x.
    1. Fischer K, Pendu R, van Schooten CJ, van DK, Denis CV, et al. (2009) Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS One 4: e6745.
    1. Nossent AY, Van Marion V, Van Tilburg NH, Rosendaal FR, Bertina RM, et al. (2006) von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 4: 2556–2562.
    1. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, et al. (1996) Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 88: 2951–2958.
    1. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, et al. (2006) Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 108: 3344–3351.
    1. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, et al. (1999) von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 94: 179–185.
    1. Hytten F (1985) Blood volume changes in normal pregnancy. Clin Haematol 14: 601–612.
    1. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367: 1066–1074.
    1. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, et al. (2011) Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 118 Suppl 11–203 10.1111/j.1471-0528.2010.02847.x [doi]
    1. Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle MH, et al. (2009) Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth 9: 55 1471-2393-9-55 [pii];10.1186/1471-2393-9-55 [doi]
    1. Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, et al. (2008) Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 99: 331–337.
    1. Sonneveld MA, de Maat MP, Leebeek FW (2014) Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 28: 167–178 S0268-960X(14)00034-4 [pii];10.1016/j.blre.2014.04.003 [doi]
    1. Sanders YV, Eikenboom J, de Wee EM, van der Bom JG, Cnossen MH, et al. (2013) Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 11: 845–854 10.1111/jth.12194 [doi]
    1. van Schie MC, van Loon JE, de Maat MP, Leebeek FW (2011) Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost 9: 899–908.
    1. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE (1997) Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96: 1102–1108.
    1. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, et al. (2002) von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23: 1764–1770 10.1053/euhj.2001.3237.
    1. Federici AB (2006) VWF propeptide: a useful marker in VWD. Blood 108: 3229–3230 10.1182/blood-2006-09-043117.
    1. Hollestelle MJ, Donkor C, Mantey EA, Chakravorty SJ, Craig A, et al. (2006) von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. British Journal of Haematology 133: 562–569.
    1. Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, et al. (2007) ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. Journal of Thrombosis and Haemostasis 5: 2284–2290.
    1. Casonato A, Gallinaro L, Cattini MG, Sartorello F, Pontara E, et al. (2010) Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. Transl Res 155: 200–208.
    1. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, et al. (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111: 3540–3545.
    1. Sztukowska M, Gallinaro L, Cattini MG, Pontara E, Sartorello F, et al. (2008) Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 143: 107–114 BJH7311 [pii];10.1111/j.1365-2141.2008.07311.x [doi]
    1. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, et al. (1997) von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost 77: 1104–1108.
    1. Sanchez-Luceros A, Meschengieser SS, Marchese C, Votta R, Casais P, et al. (2003) Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 14: 647–651.
    1. Caires D, Rocha-Pinango CL, Rodriguez S, Linares J (1984) Factor VIIIR: Ag/Factor VIII:C and their Ratio in Obstetrical Cases. Acta Obstetricia et Gynecologica Scandinavica 63: 411–416 10.3109/00016348409156694.
    1. Fournie A, Monrozies M, Pontonnier G, Boneu B, Bierme R (1981) Factor VIII complex in normal pregnancy, pre-eclampsia and fetal growth retardation. Br J Obstet Gynaecol 88: 250–254.
    1. Ogawa T, Suzuki Y, Sayama S, Soma H (1983) Possible relationship between the ratio of Factor VIII complex and placental insufficiency in preeclampsia. Biol Res Pregnancy Perinatol 4: 155–157.
    1. Thornton CA, Bonnar J (1977) Factor VIII-related antigen and factor VIII coagulant activity in normal and pre-eclamptic pregnancy. Br J Obstet Gynaecol 84: 919–923.
    1. Fuchs B, de Witt S, Solecka BA, Kroning M, Obser T, et al. (2013) Distinct role of von Willebrand factor triplet bands in glycoprotein Ib-dependent platelet adhesion and thrombus formation under flow. Semin Thromb Hemost 39: 306–314 10.1055/s-0032-1328971 [doi]
    1. Sadler JE (2005) von Willebrand factor: two sides of a coin. J Thromb Haemost 3: 1702–1709.
    1. Defaus S, Gupta P, Andreu D, Gutierrez-Gallego R (2014) Mammalian protein glycosylation—structure versus function. Analyst 139: 2944–2967 10.1039/c3an02245e [doi]
    1. Stockschlaeder M, Schneppenheim R, Budde U (2014) Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 25: 206–216 10.1097/MBC.0000000000000065 [doi]
    1. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, et al. (2005) Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3: 79–84 JTH1033 [pii];10.1111/j.1538-7836.2004.01033.x [doi]
    1. Jenkins PV, Rawley O, Smith OP, O'Donnell JS (2012) Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol 157: 653–663 10.1111/j.1365-2141.2012.09134.x [doi]
    1. American Association of Blood Banks (2008) Frequency of ABO in the U.S. Population. 2008.

Source: PubMed

3
Subscribe